Search results for: Health Policy and Regulation

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

1 February 2019

…evaluate the clinical and economic value of health care interventions − prescription drugs, diagnostic tests, and a range of others − and innovations in the delivery of care. ICER involves…

OHE

With over 60 years of expertise, the Office of Health Economics (OHE) is the world’s oldest independent health economics research organisation. We are a registered charity and an Independent Research…

Medical Care in Developing Countries

1 November 1972

…change in their patterns of morbidity and mortality. For example, between 1848 and 1872 it has been estimated that over 32 per cent of all male deaths in England and…

The Impact of New Medicines in the NHS: 70 Years of Innovation

1 August 2018

…have been brought to market, and from a review of the literature and evidence base we attempt to quantify the benefits of these key medicines in terms of health and…

Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015

20 January 2015

…use of a natural experiment to explore the relationship between use of formal and informal care in Scotland.   The abstracts and full programme are available on the HESG website….

Patricia Cubi-Molla

4 September 2015

Patricia is a mathematician and a health economist, with expertise in the use of patient-reported outcome measures in decision-making. Her primary interests include health and wellbeing impact assessment, efficient resource…

Comparing the EQ-5D-3L and EQ-5D-5L in a Cohort of Cancer Patients: A Research Collaboration between OHE, Curtin University and King’s College London

15 August 2017

…of the 3L and 5L instruments to different patient and disease characteristics; If the 5L instrument systematically gives different responses and values compared to 3L, and what effect this has…